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ORIGINAL
RESEARCH
Effectiveness of Mechanical Endovascular
Thrombectomy in a Model System of
Cerebrovascular Occlusion
J.Y. Chueh
A.K. Wakhloo
M.J. Gounis
BACKGROUND AND PURPOSE: A number of thrombectomy devices are currently undergoing clinical
evaluation; meanwhile, various novel devices are under investigation. The aims of this study were to
quantify flow restoration and the particle size distribution of the effluent pursuant to MET in an in vitro
occlusion model.
MATERIALS AND METHODS: The model system was composed of 3 elements: an ICA/MCA replica, a
clot model with mechanical properties similar to those of thrombi found in patients at risk of stroke, and
a pulsatile flow loop. Different thrombectomy mechanisms including mechanical retrieval, aspiration,
and waveguide induced cavitation were used. The efficacy end points were recanalization rate and
amount of flow restoration. The risk of the embolic shower was assessed to evaluate device safety.
RESULTS: The recanalization rates were the following: Merci, 67%; Solitaire, 100%; Penumbra, 83%;
Enterprise, 17%; and the waveguide, 0%. In experiments in which recanalization was achieved, the
amount of flow restoration for the Merci, Solitaire, and Enterprise devices was 100%, 92%, and 86%,
respectively. The mean sizes of generated small and large clot fragments were between 23 and 37 and
215 and 285 m, respectively, depending on the device used. The Merci device generated the fewest
number of large fragments compared with the Penumbra system (P  .05) and Solitaire (not
significant).
CONCLUSIONS: The risk of embolic shower was influenced by the mechanism of action for the
thrombectomy device. Clinically reported recanalization rates for the Solitaire, Penumbra, and Merci
devices were nearly identical in this model system, suggesting that this model may provide a
predictive tool for preclinical evaluation of MET.
ABBREVIATIONS: AIS  acute ischemic stroke; CCA  common carotid artery; ECA  external
carotid artery; MERCI  Mechanical Embolus Removal in Cerebral Ischemia; MET  mechanical
endovascular thrombectomy
Prompt recanalization of the occluded vessel in AIS mayreduce the amount of brain destined for infarction.1-3 Pre-
vious studies have shown that MET allows AIS treatment in
patients contraindicated for treatment with intravenous re-
combinant tissue plasminogen activator.4,5 However, further
improvement in the effectiveness and thus clinical outcome of
MET devices is desired.
The feasibility of using the retrievable stent to extract the
thrombotic material from an occluded vessel has been dem-
onstrated in the porcine model.6 This technique is now being
evaluated in several ongoing clinical trials.7,8 Sonographically
driven waveguides have been used for thrombus-ablation ap-
plications in the peripheral vasculature.9,10 In the present
work, this concept is expanded to the ablation of cerebrovas-
cular occlusion, in which the vessel geometry is more complex
and tortuous.
We hypothesized that an experimental model system of
cerebrovascular occlusion can be built to allow quantification
of the flow restoration and characterization of the distal em-
boli. With these preliminary data, the effectiveness and safety
of different thrombectomy techniques can be assessed before
their clinical use.
Materials and Methods
A Model System of Cerebrovascular Occlusion
An ICA/MCA replica with an ICA siphon average curvature of 0.4
mm1, a diameter of 4.2mm, and length of 20.6mmwas constructed
by using a small-batch processing method, as previously reported.11
The MCA diameter at the site of the occlusion measured 2.1 mm. In
brief, the geometry of the vasculature was obtained from brain MRA
data and was used to create a mold with core-shell structure for sili-
cone infusion. After dissolution of the mold, a layer of LSR topcoat
(Momentive Performance Materials, Albany, New York) was applied
to the innerwall of the ICA/MCA silicone replica to provide enhanced
lubricity for the delivery of endovascular devices. To create the MCA
occlusion, a thrombin-induced radiopaque bovine clot model (10
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mm in length) was delivered and carried with the flow, where it be-
came lodged in the MCA. This particular clot model mimicked the
thrombus extracted from the atherosclerotic plaques and was formed
from amixture of bovine blood, thrombin (2.5NIHunits/mL blood),
and barium sulfate (1 g/10 mL blood).12
The flow loop (Fig 1) established in this study consisted of a pro-
grammable piston pump (ShelleyMedical ImagingTechnologies, To-
ronto, Ontario, Canada), a blood-mimicking fluid (60%/40% by vol-
ume water/glycerin), custom-built Starling resistors chambers, and a
data-acquisition system. Flow into the circulation loop as well as
through the ICA/MCA replica was recorded digitally with sono-
graphic flow probes (Transonic Systems, Ithaca, New York). Addi-
tionally, pressure was recorded proximal and distal to the site of oc-
clusion by using variable reluctance differential pressure transducers
(Validyne Engineering Corporation, Northbridge, California). A
physiologically realistic flow waveform was generated by the pump,
simulating human cerebrovascular hemodynamics. The blood analog
fluid traveled through the external carotid artery and was directed to
a filtration system before re-entering the reservoir; on the other hand,
fluid traveling through the ICA loop was collected for particle analy-
sis. The Starling resistors simulated the peripheral arterial resistance
and controlled the pressure within the physiologic range.13 The data
acquisition system (Dewetron, Charlestown, Rhode Island) recorded
the real-time flow and pressure. It also incorporated the synchronized
video captured by a digital camcorder.
Thrombectomy Procedure
The Merci L5 retriever (Concentric Medical, Mountain View, Cali-
fornia), Enterprise stent (Codman Neurovascular, Raynham, Massa-
chusetts), Solitaire FR revascularization device (ev3, Irvine, Califor-
nia), Penumbra 054 aspiration system (Penumbra, Alameda,
California), and an ultrasound waveguide system (OmniSonicsMed-
ical Technologies, Wilmington, Massachusetts) were tested in this
study. Each device was deployed according to the manufacturer’s
instructions.
To deliver the Merci retriever (helix loop of 4.5 mm in length and
2.5 mm in diameter), an 8F balloon-guide catheter was positioned in
the proximal ICA. Navigation of the Merci microcatheter 18L
through the clot was performed over the wire under fluoroscopic
navigation. The guidewire was exchanged for the Merci retriever,
which was deployed beyond the occlusive clot. The corkscrew-shaped
retriever engaged the clot and was pulled back into the guide catheter
under proximal temporary balloon occlusion of the ICA. Aspiration
through the balloon guide catheter was applied during clot retrieval.
The Enterprise stent (28 mm in length and 4.5 mm in diameter)
has a closed-cell design and can be resheathed after up to 70%deploy-
ment. For stent-based thrombectomy, a 6F guide catheter was placed
in the proximal ICA. A 2.3F microcatheter was navigated over the
wire to the distal end of the occlusive clot. The guidewire was with-
drawn followed by partial stent deployment within the occlusion for
clot retrieval. During the retrieval, aspiration was applied through the
central lumen of guide catheter. The procedure was performed with-
out proximal flow arrest.
The Solitaire FR revascularization device (20 mm in length and 4
mm in diameter) can be fully deployed, resheathed, and retrieved.
The procedure used for the Enterprise deployment was applied to the
Solitaire FR revascularization device, except that an 8F balloon guide
catheter was positioned in the ICA and inflated to temporarily arrest
the proximal flow during clot retrieval per the instructions of the
manufacturer.8
The Penumbra 054 aspiration system, consisting of a reperfusion
catheter, separator, aspiration tubing, and suction pump, was set up
for clot removal. A 7F guide catheter was positioned in the proximal
ICA, and the reperfusion catheter was advanced to the proximal as-
pect of the occlusion. The vacuum pump was operated, and the sep-
arator was inserted into the reperfusion catheter. The side port of the
rotating hemostasis valve was connected to the aspiration tubing.
During aspiration, the separator was advanced and retracted to assist
with clot removal.
The waveguide system was composed of a function generator,
a transducer, and a thrombectomy wire (156 cm in length and
0.4 mm in diameter). A 6F guide catheter was positioned in the ICA,
and through this, a 2.8F microcatheter was positioned across the
occlusive clot. The thrombectomy wire was delivered through the
microcatheter, whichwas thenwithdrawn to expose the active section
of the wire. The piezoelectric transducer was coupled on the proximal
end to the wire, which causes high-frequency vibration to the distal
active section. The mechanical motion of the active section produced
cavitation streaming, which was necessary to fracture the fibrin
matrix of the clot. The system was operated within the clot for
20 minutes.
Six experiments were performed for each device, and the experi-
mental sequence was randomized. The maximum number of throm-
bectomy attempts was 3. The balloon-guide catheter was positioned
Fig 1. Schematic of the experimental system that includes
ECA and ICA circulation loops. The flow through the ECA loop
is filtered and recirculated, whereas the effluent of the ICA
loop where the MET is performed is captured for particulate
analysis. Location of the flow sensors and pressure trans-
ducers is noted. Use of an anastomosis between the distal
ICA and ECA along with the Starling resistors maintains a
physiologic pressure gradient across the MCA occlusion.
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in the ICA to temporarily arrest the flowduring the clot removalwhen
using the Merci retriever (n  6) and the Solitaire FR (n  5). One
Solitaire test was excluded from data analysis due to the failure of
proximal flow arrest. All procedures were performed under x-ray
guidance (Allura FD20; Philips Healthcare, Best, the Netherlands) by
the senior interventional neuroradiologist (20 years of experience).
Efficacy and Safety End Points
The primary efficacy end point was the amount of blood flow re-
stored, which was defined as a ratio of flow in the ICA/MCA replica
postprocedurally divided by the flow before creation of the occlusion.
Follow-up angiography was performed to confirm the vessel patency
for determination of the recanalization rate as the secondary efficacy
end point.
The primary safety end point was the number and size of the clot
fragments within the effluent of the ICA loop during MET. To mea-
sure the particulate size and size distribution, a Coulter counter
(Beckman Multisizer 4, Brea, California) was used. In each experi-
ment before the occlusion, 400 mL of blood-mimicking solution was
collected as a blank for particle analysis. The blank sample accounted
for microscopic background particles that were present in the flow
loop. During MET, clot particulates with size between 200 and 1200
m and 10 and 240 m were measured by the 2000 and 400 m
apertures, respectively. Therefore, using 2 different apertures allowed
complete particulate characterization of fragments within the range
of 10–1200 m. A large volume of blood-mimicking solution was
required for each analysis with the use of a 2000-maperture. There-
fore, the number of particle analysis tests was determined depending
on the volume of solution collected during each experiment (between
1 and 2 analyses performed per experiment). Up to 5 replicate partic-
ulate tests were conducted by using the smaller 400-m aperture.
Statistical Analysis
All data were shown as mean standard error of the mean. To com-
pare the results from the particulate measurements, we used a non-
parametric 1-way analysis of variance (Kruskal-Wallis) with Dunn
posttests (Prism 5; GraphPad, LA Jolla, California). This method of
analysis makes no assumption about the distribution of the data. Sta-
tistical significance was set at P .05.
Results
Flow Restoration
Before occlusion, CCA and MCA flows were 363  1.9 mL/
min and 132  1.4 mL/min, respectively (physiologic CCA
flow, 378–450 mL/min; MCA flow, 117–152 mL/min14). The
pressure gradient between the proximal and distal MCA was
21  0.7 mm Hg. After occlusion, an increase in pressure
gradient was observed (44 2.4mmHg), and completeMCA
occlusion was confirmed (Fig 2).
TheMerci retriever, Solitaire FR, and Enterprise stent were
all able to engage the clot after deployment. To successfully
restore flow, the clot slowly traveled through the ICA and was
aspirated into the guide catheter (Fig 3A–D). In some experi-
ments, the clot detached from the device when passing the
tortuous ICA siphon, resulting in partial or failed thrombec-
tomy (Fig 4A–D). Overall, the Solitaire FR achieved the high-
est recanalization rate (100%) followed by the Merci retriever
(67%) and Enterprise stent (17%). The average number of
passes with the Solitaire FR, Merci retriever, and Enterprise
stent was 1.2, 1.8, and 2.3, respectively. On average, the Soli-
taire FR restored 92.4  4.5% of flow. The Merci retriever
restored 100% of flow in 4 experiments; however, in 2 exper-
iments, the retriever was not able to ensnare the clot fragments
during clot retrieval, resulting in a large portion of clot re-
tained at theMCA bifurcation. Failure to recanalize themodel
was recorded in these 2 experiments. Flow restoration (29.2
6.4%) was measured when the Enterprise stent was deployed
within the clot, creating a temporary endovascular bypass. In 1
of the 6 experiments performed with the Enterprise stent,
86.6% flow was restored when part of the clot was removed by
the device.
When the Penumbra aspiration system was used (Fig 5A–
D), the continuous aspiration-debulking process produced
visible clot particulates (circle in Fig 5B). After 2–3 passages of
the aspiration device through the occluded area, 100% flow
restoration was seen in 2 tests, partial flow restoration was
measured in 3 tests, and no flow restoration was recorded in 1
test. Overall, the use of the Penumbra aspiration system
showed a recanalization rate of 83% and an average of 92.5
4.6% flow restoration. Activation of the ultrasoundwaveguide
Fig 2. Variations of the hemodynamic variables before and
after clot introduction.
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failed to clear the occlusion. Although a blood plume was ob-
served and small clot particles were generated during the acti-
vation of thewaveguide, no flow restorationwas achieved. The
recanalization rate and flow restoration of each device (except
the waveguide) are presented in Fig 6A, -B, respectively.
Particulate Analysis
The blank-subtracted results showed that thousands of small
clot fragments with sizes smaller than 240mwere released by
each device, and most particulates (80.6%–92.1%, depending
on the device used) measured between 10 and 50 m. The
2000-maperture detected that90%of large clot debris had
a size between 200 and 400m.Themean size of the small and
large clot fragments was between 23  2.9 m and 37  5.1
m and 215 5.4 and 285 26.0 m, respectively, depend-
ing on the device used (Fig 6C, -D). There was a significant
increase in thenumberof large clot fragmentswith thePenumbra
aspiration system compared with the Merci retriever (P .05).
The Penumbra aspiration device generated more fragments and
the Solitaire FR produced larger fragments than the waveguide
Fig 3. A, The Solitaire FR (asterisk) is deployed within the
clot. Successful clot mobilization by the Solitaire FR is dem-
onstrated in B. C, Flow restoration is presented on the
postprocedure angiogram. D, The flow sensor detects com-
plete recanalization.
Fig 4. A, The clot is encased by the Enterprise stent struts
after partial deployment. B, Clot is disrupted in 2 pieces, and
1 is retrieved along with the stent. C and D, The retrieved clot
is not retained within the stent struts when traveling through
the ICA siphon. The asterisk indicates the distal radiopaque
markers of the Enterprise stent.
Fig 5. Partial recanalization of the MCA by using the Pen-
umbra aspiration system. A, The reperfusion catheter (arrow)
is placed at the proximal end of the clot. B, The clot is
aspirated into the aspiration catheter with the assistance of
the separator (asterisk). Small clot fragments (circle) are
generated during the procedure. C, A small portion of clot is
retained at 1 of the MCA branches. D, Partial flow restoration
is achieved.
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(P .05).However, because thewaveguide failed to restore flow,
this result was expected.
Discussion
In this study, the presented in vitro model system of cerebro-
vascular occlusion offers a reproducible testing environment
to evaluate existing devices and/or newly developed proto-
types. Performing MET in the aforesaid model system allows
one to quantitatively determine the flow restoration and gen-
eration of clot fragments in the effluent. Currently, the existing
in vitro experimental occlusion models for MET testing typi-
cally use stenosed straight tubing with clots prepared by using
a variety of methods.15-18 The straight tubing does not repro-
duce the anatomic setting of the human cerebrovasculature.
To improve these shortcomings, we selected the ICA siphon
with moderate tortuosity from a patient population. It was
built to allow realistic device tracking and was the key feature
of the proposed ICA/MCA replica.
The similarities between mechanical properties of the hu-
man sources of cerebral emboli19 and the laboratory clotmod-
els16-18,20 are often ignored. The radiopaque bovine clotmodel
used in this work mimicked aged thromboemboli from ath-
erosclerotic plaques and was selected for creation of MCA oc-
clusions due to its low elasticity and hence high propensity for
fragmentation. This enabled the evaluation ofMET in aworst-
case clinical scenario. Due to the variability in mechanical
properties of thromboemboli from different sources,12 testing
with 1 clot model is a limitation of this study. Future work
should continue to evaluate the efficacy and safety envelope of
each device technology on the basis of embolus characteristics.
Thereafter, it may be possible to select the most appropriate
thrombectomy device on the basis of clues of embolus com-
position, perhaps deduced from clinical evidence of the source
of embolism or with imaging.21
The effectiveness of the Penumbra aspiration system,
Merci retriever, and Solitaire FR in the described experimental
occlusionmodel was consistent with that demonstrated in the
previous clinical trials. The Penumbra Pivotal Stroke Trial
showed a recanalization (Thrombolysis in Myocardial Infarc-
tion grade 2 or 3) rate of 81.6%,5 which was nearly the same as
that in our experiment (83%). Similarly, the observed recan-
alization rate in this model system when using the Merci re-
triever (67%)or Solitaire FR (100%)was comparablewith that
reported in the Multi-MERCI registry (57.3%)4 and a recent
case series that used the Solitaire (83–90%).26 These results
may serve as evidence in support of the role of the proposed
occlusion model in realistic assessment of device efficacy.
Mechanical clot retrieval was conducted by using theMerci
retriever, Solitaire FR, and Enterprise stent in this study.
Among these 3 groups, it was more frequent to find the disen-
gagement of clot from the Enterprise stent during the retrieval
process, in particular when clot traveled through the ICA si-
phon where higher tortuosity and larger vessel diameter were
encountered. Notably, this device was not designed as a clot
retriever. The resulting low recanalization rate of the Enter-
prise stent (17%) could be attributed to the lack of proximal
flow control without the use of a temporary occlusion of the
ICA. As a consequence of this limitation, the continuous an-
tegrade flow in the system tended to carry the clot
downstream.
The presence of realistic siphon tortuosity may be, in part,
responsible for the unsuccessful recanalization of the wave-
guide driven thrombectomy. Clot disruption caused by the
waveguide in straight tubing was demonstrated in previous
studies.9,18,22 Our experience (data not shown) is that the de-
vice led to clot ablation due to the high-frequency vibration of
the distal active section when tested in straight or mildly tor-
tuous tubing. However, when the same technique was applied
to the ICA/MCA occlusion, no flow restoration was seen.
Therefore, it was reasonable to assume that the tortuosity of
the cerebrovasculature impeded the ultrasound wave propa-
gation and, in part, accounted for the failure to restore flow. In
clinical practice, intra-arterial mechanical techniques are very
often used in conjunction with a thrombolytic agent such as
Fig 6. Recanalization rate (A) and amount of flow restored (B)
with the use of Solitaire FR, Penumbra aspiration system,
Merci retriever, and Enterprise stent are shown. Quantitative
results of fragment number and size are presented in C and
D, respectively. Error bars are the standard error of the mean,
and the asterisk indicates P  .05.
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urokinase or tPA; these combinations may have an enhanced
effect on revascularization. However, in past research with the
waveguide device in vitro, the addition of tPA did not improve
recanalization effectiveness.18
Our in vitro model uses a blood analog solution consisting
of water and glycerin, which matches the rheologic properties
of blood under the flow conditions of our experiment. Al-
though this creates an accurate hemodynamic environment,
this model is not easily amendable to the use of thrombolytics
due to the lack of circulating plasminogen. Although adjunc-
tive pharmacologic thrombolysis may have produced some
benefit in this model, the results would be difficult to translate
into clinical practice due to the limitation imposed by the use
of a blood analog solution.
Size and size distribution of the clot particulates released
during the thrombectomy procedure described the potential
risk of distal embolic shower. The Coulter principle was ap-
plied in 2 prior ex vivo studies to count and size the embolic
fragments from the human atherosclerotic plaques that were
released with ex vivo carotid angioplasty,23,24 and the authors
concluded that hundreds of thousands of microemboli were
generated during angioplasty. In this study, we calculated and
compared the mean number of clot fragments in the effluent
following MET with different devices. Similarly, thousands of
microemboli were found in every 400mL of blood-mimicking
solution analyzed. It is critical to note that part of these frag-
ments may be introduced into the system during the course of
the experiment. Although every effort was made to reduce
introduction of the particulates and subtraction of the blank
samples acquired immediately before each experiment was
performed, this study was not conducted in a clean room, and
as such, this is a limitation of the research presented.However,
the large particles generated were confirmed by visual inspec-
tion to be clot fragments. In our model system, the Penumbra
aspiration catheter generated more large particles than the
Merci system. This finding potentially explains the contradic-
tory clinical evidence that despite the high recanalization rate
realized with this device, the favorable clinical outcomes are
reportedly less frequent5 than with either the Solitaire8 or
Merci4 devices.
Although the risk of embolic shower calculated by using
this in vitro model system is an important safety metric, vas-
cular response and potential injury to the device used are of
paramount importance. These cannot be assessed by using in
vitro modeling, and consequently preclinical assessment in
animal models is still required.25
Conclusions
In this study, the presented in vitro model system of cerebro-
vascular occlusion offers a reproducible testing environment
to quantitatively evaluate existing devices and/or newly devel-
oped prototypes, which cannot be precisely measured in cur-
rent animalmodels. The results showed that the recanalization
rate of the thrombectomy device was related to the ability of
the device to capture the clot during removal and the geometry
of the cerebrovasculature. The risk of embolic shower was in-
fluenced by the mechanism of action for the thrombectomy
device. As more devices become available, testing in such a
preclinical model system may provide an efficient means for
device development.
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